Multicenter prospective observational study on minimal residual disease of ALL after allogeneic transplantation using circulating cell-free tumor DNA KSGCT1901(ctALL)

Multicenter prospective observational study on minimal residual disease of ALL after allogeneic transplantation using circulating cell-free tumor DNA KSGCT1901(ctALL) - Prospective study on MRD of ALL after transplant using ctDNA, KSGCT1901(ctALL)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000039899

Enrollment

Registered

2020-03-23

Start date

2020-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphocytic leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients age >= 16 years 2) Precursor Lymphoid neoplasms, Chronic myeloid leukeamia, BCR-ABL1-positive in blastic phase (not including myeloid crisis), and mixed-phenotype acute leukeamia with t(9;22) 3) No limit on the disease stage or chemosensitivity at the time of transplant 4) Patients in which a high-quality sample with a tumor volume of 20% or more (at the time of initial diagnosis or relapse) is available. 5) Patients who may undergo allogeneic transplantation at the time of registration. 6)Patients who were informed and concented

Exclusion criteria

Exclusion criteria: Patients who are otherwise classified as unfit by the attending physicians for this research.

Design outcomes

Primary

Measure	Time frame
One-year cumulative incidence of ALL relapse	—

Secondary

Measure	Time frame
One-year overall survival, Somatic gene mutation, gene expression and immune cell profile at initial diagnosis and relapse	—

Countries

Japan

Contacts

Public ContactHiroto Ishii

Jikei University School of Medicine Division of Clinical Oncology and Hematology

ksgctdc@ksgct.net03-3433-1111

Outcome results